MAPT and frontotemporal dementia: have proposed that the development of small molecule β-arrestin2 oligomerization inhibitors may have therapeutic relevance for intervention in frontotemporal dementia (FTD) form-tau to enhance the elimination of the tau protein without exerting significant side effects via GPCR signaling pathways.